Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?
Aged
Antineoplastic Agents, Immunological
/ administration & dosage
Biomarkers, Tumor
/ antagonists & inhibitors
Case-Control Studies
Enzyme-Linked Immunosorbent Assay
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
/ drug therapy
Male
Middle Aged
Neoplasm Staging
Odds Ratio
Peptide Hormones
/ antagonists & inhibitors
Prospective Studies
ROC Curve
Risk Factors
Apelinergic system
Apoptosis
Chronic lymphocytic leukaemia
ELABELA
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
12 Nov 2019
12 Nov 2019
Historique:
received:
21
06
2019
accepted:
01
11
2019
entrez:
14
11
2019
pubmed:
14
11
2019
medline:
31
3
2020
Statut:
epublish
Résumé
It has been shown that bcl2, bcl-XL and mcl-1 protein levels are high in chronic lymphocytic leukemia cells, and resultantly, apoptosis does not occur chronic lymphocytic leukemia cells. Apelin and apela (ELABELA/ELA/Toddler) are two peptide ligands for a class A G-protein coupled receptor called apelin receptor. Studies have shown that ELA inhibits apoptosis by inhibiting apoptotic proteins and activating anti-apoptotic proteins. Proteins and genes involved in apoptosis are valuable for targeted cancer therapy. We hypothesized that serum levels may be increased in patients with chronic lymphocytic leukemia based on the antiapoptotic effect of ELA. We compared serum ELABELA levels of healthy volunteers and patients with chronic lymphocytic leukemia. We aimed to draw attention to a new molecule worthy of research in targeted cancer treatment. Forty two untreated CLL patients and 41 healthy volunteers were included in the study. Serum ELA levels were measured by using enzyme-linked immunosorbent assay kits (Dhanghai Sunred Biological Technology co. Ltd), automated ELISA reader (Thermo Scientific, FİNLAND) and computer program (Scanlt for Multiscan F.C.2.5.1) in accordance with the manufacturer's instructions. Statistical analysis was done by Statistical Package for Social Sciences for Windows 20 (IBM SPSS Inc., Chicago, IL) ve MedCalc programs. ELA and variables related to CLL were correlated with Spearman correlation anlysis test. ROC analysis and Youden index method were used to determine a cut off point for ELA. All p-values were 2-sided with statistical significance at 0.05 alpha levels. In our study, we found that serum ELA levels were significantly higher in patients with CLL. This study highlights that ELA targeting may be a potential therapeutic option for treating CLL.
Sections du résumé
BACKGROUND
BACKGROUND
It has been shown that bcl2, bcl-XL and mcl-1 protein levels are high in chronic lymphocytic leukemia cells, and resultantly, apoptosis does not occur chronic lymphocytic leukemia cells. Apelin and apela (ELABELA/ELA/Toddler) are two peptide ligands for a class A G-protein coupled receptor called apelin receptor. Studies have shown that ELA inhibits apoptosis by inhibiting apoptotic proteins and activating anti-apoptotic proteins. Proteins and genes involved in apoptosis are valuable for targeted cancer therapy. We hypothesized that serum levels may be increased in patients with chronic lymphocytic leukemia based on the antiapoptotic effect of ELA. We compared serum ELABELA levels of healthy volunteers and patients with chronic lymphocytic leukemia. We aimed to draw attention to a new molecule worthy of research in targeted cancer treatment.
METHODS
METHODS
Forty two untreated CLL patients and 41 healthy volunteers were included in the study. Serum ELA levels were measured by using enzyme-linked immunosorbent assay kits (Dhanghai Sunred Biological Technology co. Ltd), automated ELISA reader (Thermo Scientific, FİNLAND) and computer program (Scanlt for Multiscan F.C.2.5.1) in accordance with the manufacturer's instructions. Statistical analysis was done by Statistical Package for Social Sciences for Windows 20 (IBM SPSS Inc., Chicago, IL) ve MedCalc programs. ELA and variables related to CLL were correlated with Spearman correlation anlysis test. ROC analysis and Youden index method were used to determine a cut off point for ELA. All p-values were 2-sided with statistical significance at 0.05 alpha levels.
RESULTS
RESULTS
In our study, we found that serum ELA levels were significantly higher in patients with CLL.
CONCLUSIONS
CONCLUSIONS
This study highlights that ELA targeting may be a potential therapeutic option for treating CLL.
Identifiants
pubmed: 31718601
doi: 10.1186/s12885-019-6325-6
pii: 10.1186/s12885-019-6325-6
pmc: PMC6849261
doi:
Substances chimiques
APELA protein, human
0
Antineoplastic Agents, Immunological
0
Biomarkers, Tumor
0
Peptide Hormones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1086Références
Gene Expr Patterns. 2010 Feb-Mar;10(2-3):127-34
pubmed: 20153842
Dev Cell. 2013 Dec 23;27(6):672-80
pubmed: 24316148
Onco Targets Ther. 2017 Jun 29;10:3215-3224
pubmed: 28721072
J Clin Pathol. 2019 May;72(5):343-346
pubmed: 30712002
EMBO Rep. 2017 Apr;18(4):536-548
pubmed: 28264987
Cell Stem Cell. 2015 Oct 1;17(4):435-47
pubmed: 26387754
Gynecol Oncol. 2017 Dec;147(3):663-671
pubmed: 29079036
J Biol Chem. 2005 Mar 18;280(11):10781-9
pubmed: 15642728
Chin Med J (Engl). 2009 Oct 5;122(19):2360-5
pubmed: 20079140
Blood. 1975 Aug;46(2):219-34
pubmed: 1139039
Blood. 2008 Jun 15;111(12):5446-56
pubmed: 18216293
Oncotarget. 2017 Apr 10;8(31):51108-51122
pubmed: 28881634
Elife. 2017 Nov 09;6:
pubmed: 29117894
Theranostics. 2013;3(1):26-33
pubmed: 23382783
Science. 2014 Feb 14;343(6172):1248636
pubmed: 24407481
J Leukoc Biol. 2003 Jun;73(6):689-701
pubmed: 12773501
Blood. 2017 Aug 31;130(9):1081-1088
pubmed: 28724540
Eur J Cardiothorac Surg. 2012 Feb;41(2):368-75
pubmed: 21683606
Acta Biochim Biophys Sin (Shanghai). 2017 Jun 1;49(6):471-478
pubmed: 28407045
Pharmaceuticals (Basel). 2019 Mar 26;12(1):null
pubmed: 30917521
Anticancer Agents Med Chem. 2009 Jun;9(5):550-9
pubmed: 19519296
Trends Biochem Sci. 2002 Sep;27(9):462-7
pubmed: 12217521
Blood. 1998 May 1;91(9):3379-89
pubmed: 9558396
Arch Med Res. 2014 Feb;45(2):158-69
pubmed: 24486245
Cell Stem Cell. 2015 Jun 4;16(6):669-83
pubmed: 25936916
Cancer Discov. 2019 Feb;9(2):156
pubmed: 30647052
Clin Exp Pharmacol Physiol. 2016 May;43(5):569-79
pubmed: 26918678
Int J Mol Med. 2015 Sep;36(3):733-8
pubmed: 26135903
Eur J Cancer Care (Engl). 2004 Jul;13(3):279-87
pubmed: 15196232
Cold Spring Harb Perspect Med. 2016 Jun 01;6(6):
pubmed: 27194168
Toxicol Lett. 2017 Mar 5;269:15-22
pubmed: 28111160